JP2016175913A5 - - Google Patents

Download PDF

Info

Publication number
JP2016175913A5
JP2016175913A5 JP2016078990A JP2016078990A JP2016175913A5 JP 2016175913 A5 JP2016175913 A5 JP 2016175913A5 JP 2016078990 A JP2016078990 A JP 2016078990A JP 2016078990 A JP2016078990 A JP 2016078990A JP 2016175913 A5 JP2016175913 A5 JP 2016175913A5
Authority
JP
Japan
Prior art keywords
polypeptide
domain
seq
mouse
modified human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016078990A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016175913A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016175913A publication Critical patent/JP2016175913A/ja
Publication of JP2016175913A5 publication Critical patent/JP2016175913A5/ja
Pending legal-status Critical Current

Links

JP2016078990A 2010-07-13 2016-04-11 抗血管新生剤及びこのような薬剤の使用方法 Pending JP2016175913A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36393310P 2010-07-13 2010-07-13
US61/363,933 2010-07-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013519804A Division JP6353654B2 (ja) 2010-07-13 2011-07-13 抗血管新生剤及びこのような薬剤の使用方法

Publications (2)

Publication Number Publication Date
JP2016175913A JP2016175913A (ja) 2016-10-06
JP2016175913A5 true JP2016175913A5 (enExample) 2017-02-16

Family

ID=44629339

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013519804A Active JP6353654B2 (ja) 2010-07-13 2011-07-13 抗血管新生剤及びこのような薬剤の使用方法
JP2016078990A Pending JP2016175913A (ja) 2010-07-13 2016-04-11 抗血管新生剤及びこのような薬剤の使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013519804A Active JP6353654B2 (ja) 2010-07-13 2011-07-13 抗血管新生剤及びこのような薬剤の使用方法

Country Status (12)

Country Link
US (2) US9175063B2 (enExample)
EP (2) EP3381462B1 (enExample)
JP (2) JP6353654B2 (enExample)
CN (1) CN103002904B (enExample)
AU (5) AU2011279155B2 (enExample)
CA (1) CA2804753C (enExample)
DK (1) DK2593127T3 (enExample)
ES (2) ES2923430T3 (enExample)
HU (1) HUE040205T2 (enExample)
PL (1) PL2593127T3 (enExample)
PT (2) PT2593127T (enExample)
WO (1) WO2012009471A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012009471A1 (en) * 2010-07-13 2012-01-19 Georgia State University Research Foundation Anti-angiogenic agent and method of using such agent
EP3265482B1 (en) * 2015-03-06 2025-11-05 Georgia State University Research Foundation, Inc. Integrin-targeting protein and methods of use thereof
CN110498851B (zh) * 2015-11-10 2022-10-11 孙嘉琳 一种抗肿瘤蛋白内皮抑素的衍生物及应用
CN108148117A (zh) * 2017-12-26 2018-06-12 张艳雪 一种抗菌肽的蛋白质结构特性及其研究方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008187A1 (en) * 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
AU2003273299B2 (en) * 2002-09-05 2010-04-01 Medimmune, Llc Methods of preventing or treating cell malignancies by administering CD2 antagonists
WO2005077018A2 (en) * 2004-02-06 2005-08-25 Astellas Us Llc Methods of treating skin disorders
JP5377965B2 (ja) * 2005-09-09 2013-12-25 ジョージア ステート ユニバーシティ リサーチ ファウンデーション、インコーポレイテッド 標的化された造影剤および造影剤を標的化するための方法
WO2009146099A2 (en) * 2008-04-02 2009-12-03 Georgia State University Research Foundation, Inc. Contrast agents, methods for preparing contrast agents, and methods of imaging
EP2599497A3 (en) * 2008-09-08 2013-09-25 Hoffman/Barrett, L.L.C. Porphyrazine-chemotherapeutic agents conjugates
WO2012009471A1 (en) * 2010-07-13 2012-01-19 Georgia State University Research Foundation Anti-angiogenic agent and method of using such agent

Similar Documents

Publication Publication Date Title
IL253187B (en) Novel multivalent nanoparticle-based vaccines
Liu et al. Use of baculovirus expression system for generation of virus-like particles: successes and challenges
WO2016037154A8 (en) Recombinant hiv-1 envelope proteins and their use
JP2016175913A5 (enExample)
WO2019126634A3 (en) Targeted integration of nucleic acids
WO2014018858A3 (en) Multimeric fusion protein vaccine and immunotherapeutic
WO2013044203A3 (en) Novel influenza hemagglutinin protein-based vaccines
JP2015119730A5 (enExample)
WO2014160490A8 (en) Antibody formulations
IL278014B1 (en) Anti-myostatin antibodies, polypeptides containing variable fc regions and methods of use
JP2015524422A5 (enExample)
JP2013172734A5 (enExample)
IN2015DN02546A (enExample)
NZ725079A (en) Transgene genetic tags and methods of use
HRP20192314T1 (hr) Pripravci faktora viii i postupci pripreme i njihove uporabe
MX389878B (es) Proteinas quimericas de factor viii y usos de estas.
EP2829550A3 (en) Fusion proteins forming trimers
JP2016501829A5 (enExample)
RU2015138530A (ru) Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа
EP3308798A3 (en) Polypeptides and antibodies for treating hbv infection and related diseases
RU2015155821A (ru) Вакцины против малярии
BR112019005511A2 (pt) vetores de adenovírus canino
HRP20191166T1 (hr) Stabilizirani proteini, namijenjeni imuniziranju protiv bakterije staphylococcus aureus
WO2015195218A8 (en) Polyvalent influenza virus-like particles (vlps) and use as vaccines
WO2018020324A3 (en) Virus-like particles with high-density coating for inducing the expression of antibodies